Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
暂无分享,去创建一个
M. Cam | J. Schlom | Paul L. Chariou | Karin M. Knudson | Y. Ozawa | Jing Bian | S. Gameiro | Kristin C Hicks | Christine M Minnar | T. Meyer | Sofia R. Gameiro
[1] M. Weller,et al. Immunocytokines are a promising immunotherapeutic approach against glioblastoma , 2020, Science Translational Medicine.
[2] D. Irvine,et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity , 2020, Nature Cancer.
[3] A. Mantovani,et al. Neutrophil diversity and plasticity in tumour progression and therapy , 2020, Nature Reviews Cancer.
[4] J. Wolchok,et al. The future of cancer immunotherapy: microenvironment-targeting combinations , 2020, Cell Research.
[5] J. Hubbell,et al. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours , 2020, Nature Biomedical Engineering.
[6] F. Marincola,et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.
[7] Y. Arai,et al. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade , 2020, Science Translational Medicine.
[8] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[9] A. Mantovani,et al. Diversity, Mechanisms, and Significance of Macrophage Plasticity. , 2020, Annual review of pathology.
[10] P. Lollini,et al. Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model , 2019, Cancers.
[11] J. Schlom,et al. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy , 2019, Clinical Cancer Research.
[12] D. Cescon,et al. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer , 2019, npj Breast Cancer.
[13] S. Baylin,et al. The emerging role of epigenetic therapeutics in immuno-oncology , 2019, Nature Reviews Clinical Oncology.
[14] A. Nicosia,et al. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling , 2019, Scientific Reports.
[15] C. Peano,et al. Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors , 2019, Cell.
[16] J. Schlom,et al. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12 , 2019, Journal of Immunotherapy for Cancer.
[17] D. Jackson,et al. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. , 2019, Cancer cell.
[18] M. Farrar,et al. JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors , 2019, Proceedings of the National Academy of Sciences.
[19] C. Garlanda,et al. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. , 2019, Immunity.
[20] Brian Ruffell,et al. Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.
[21] Ralph Weissleder,et al. Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.
[22] J. Schlom,et al. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types , 2018, Oncoimmunology.
[23] S. Workenhe,et al. HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. , 2018, Cell reports.
[24] J. Schlom,et al. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine , 2018, Oncoimmunology.
[25] P. Ordentlich,et al. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma , 2017, Clinical Cancer Research.
[26] J. English,et al. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models , 2017, Clinical Cancer Research.
[27] Weiping Zou,et al. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.
[28] J. Schlom,et al. Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody , 2017, Oncotarget.
[29] M. Rudek,et al. Entinostat: a promising treatment option for patients with advanced breast cancer. , 2017, Future oncology.
[30] Robert R Yauch,et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice , 2017, Nature Communications.
[31] Burkhard Becher,et al. GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. , 2016, Immunity.
[32] J. Trepel,et al. The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat , 2016, Oncoimmunology.
[33] J. Schlom,et al. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas , 2016, Oncotarget.
[34] S. Ferrone,et al. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells , 2016, Oncotarget.
[35] P. Munster,et al. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. , 2015, Epigenomics.
[36] M. Kiupel,et al. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma , 2015, PloS one.
[37] B. Becher,et al. New insights into IL-12-mediated tumor suppression , 2014, Cell Death and Differentiation.
[38] G. Adema,et al. HDAC inhibitors and immunotherapy; a double edged sword? , 2014, Oncotarget.
[39] K. Kinzler,et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.
[40] J. Schlom,et al. The immunocytokine NHS-IL12 as a potential cancer therapeutic , 2014, Oncotarget.
[41] G. Natoli,et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages , 2012, Proceedings of the National Academy of Sciences.
[42] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[43] L. Ellis,et al. Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models , 2012, PloS one.
[44] F. Marincola,et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. , 2011, The Journal of clinical investigation.
[45] J. Schlom,et al. Intratumoral Immunotherapy of Established Solid Tumors With Chitosan/IL-12 , 2010, Journal of immunotherapy.
[46] L. Moretta,et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. , 2008, Cancer letters.
[47] M. Del Vecchio,et al. Interleukin-12: Biological Properties and Clinical Application , 2007, Clinical Cancer Research.
[48] S. Steinberg,et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. , 2006, Blood.
[49] E. Sausville,et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] I. Flinn,et al. Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease , 2004, Clinical Cancer Research.
[51] J. Prieto,et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] P. Lollini,et al. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma , 1983, Clinical & Experimental Metastasis.
[53] L. Khawli,et al. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. , 2001, Hybridoma and hybridomics.
[54] M. Atkins,et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] G. Wood,et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. , 1999, Blood.
[56] U. Grohmann,et al. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. , 1998, Immunity.
[57] S. Gillies,et al. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. , 1998, Journal of immunology.
[58] G. Trinchieri,et al. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. , 1994, Cellular immunology.
[59] G. Trinchieri,et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.
[60] P. Hand,et al. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. , 1991, Cancer research.